These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 36309347)

  • 21. Ontology-Based Vaccine Adverse Event Representation and Analysis.
    Xie J; He Y
    Adv Exp Med Biol; 2017; 1028():89-103. PubMed ID: 29058218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An eHealth Intervention for Promoting COVID-19 Knowledge and Protective Behaviors and Reducing Pandemic Distress Among Sexual and Gender Minorities: Protocol for a Randomized Controlled Trial (#SafeHandsSafeHearts).
    Newman PA; Chakrapani V; Williams C; Massaquoi N; Tepjan S; Roungprakhon S; Akkakanjanasupar P; Logie C; Rawat S
    JMIR Res Protoc; 2021 Dec; 10(12):e34381. PubMed ID: 34726610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Retrospective Analysis of COVID-19 mRNA Vaccine Breakthrough Infections - Risk Factors and Vaccine Effectiveness.
    Liu C; Lee J; Ta C; Soroush A; Rogers JR; Kim JH; Natarajan K; Zucker J; Weng C
    medRxiv; 2021 Oct; ():. PubMed ID: 34642696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zhu FC; Guan XH; Li YH; Huang JY; Jiang T; Hou LH; Li JX; Yang BF; Wang L; Wang WJ; Wu SP; Wang Z; Wu XH; Xu JJ; Zhang Z; Jia SY; Wang BS; Hu Y; Liu JJ; Zhang J; Qian XA; Li Q; Pan HX; Jiang HD; Deng P; Gou JB; Wang XW; Wang XH; Chen W
    Lancet; 2020 Aug; 396(10249):479-488. PubMed ID: 32702299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
    Zhu FC; Li YH; Guan XH; Hou LH; Wang WJ; Li JX; Wu SP; Wang BS; Wang Z; Wang L; Jia SY; Jiang HD; Wang L; Jiang T; Hu Y; Gou JB; Xu SB; Xu JJ; Wang XW; Wang W; Chen W
    Lancet; 2020 Jun; 395(10240):1845-1854. PubMed ID: 32450106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Active monitoring of adverse reactions following COVID-19 and other vaccinations: a feasibility study as part of the CoVaKo project.
    Zeschick N; Warkentin L; Kühlein T; Steininger P; Überla K; Hueber S; Sebastião M
    Pilot Feasibility Stud; 2022 Jul; 8(1):134. PubMed ID: 35780172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET).
    Body A; Ahern E; Lal L; Gillett K; Abdulla H; Opat S; O'Brien T; Downie P; Turville S; Munier CML; Smith C; MacIntyre CR; Segelov E
    BMC Infect Dis; 2022 Jan; 22(1):70. PubMed ID: 35057745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Healthcare workers' perceptions and experiences of communicating with people over 50 years of age about vaccination: a qualitative evidence synthesis.
    Glenton C; Carlsen B; Lewin S; Wennekes MD; Winje BA; Eilers R;
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013706. PubMed ID: 34282603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk Factors for COVID-19 in College Students Identified by Physical, Mental, and Social Health Reported During the Fall 2020 Semester: Observational Study Using the Roadmap App and Fitbit Wearable Sensors.
    Gilley KN; Baroudi L; Yu M; Gainsburg I; Reddy N; Bradley C; Cislo C; Rozwadowski ML; Clingan CA; DeMoss MS; Churay T; Birditt K; Colabianchi N; Chowdhury M; Forger D; Gagnier J; Zernicke RF; Cunningham JL; Cain SM; Tewari M; Choi SW
    JMIR Ment Health; 2022 Feb; 9(2):e34645. PubMed ID: 34992051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Junqueira-Kipnis AP; Dos Anjos LRB; Barbosa LCS; da Costa AC; Borges KCM; Cardoso ADRO; Ribeiro KM; Rosa SBA; Souza CC; das Neves RC; Saraiva G; da Silva SM; Silveira EA; Rabahi MF; Conte MB; Kipnis A
    Trials; 2020 Oct; 21(1):881. PubMed ID: 33106170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.
    Al Kaabi N; Zhang Y; Xia S; Yang Y; Al Qahtani MM; Abdulrazzaq N; Al Nusair M; Hassany M; Jawad JS; Abdalla J; Hussein SE; Al Mazrouei SK; Al Karam M; Li X; Yang X; Wang W; Lai B; Chen W; Huang S; Wang Q; Yang T; Liu Y; Ma R; Hussain ZM; Khan T; Saifuddin Fasihuddin M; You W; Xie Z; Zhao Y; Jiang Z; Zhao G; Zhang Y; Mahmoud S; ElTantawy I; Xiao P; Koshy A; Zaher WA; Wang H; Duan K; Pan A; Yang X
    JAMA; 2021 Jul; 326(1):35-45. PubMed ID: 34037666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse Events and Immunogenicity of mRNA-Based COVID-19 Vaccine among Healthcare Workers: A Single-Centre Experience.
    Sauserienė J; Liseckienė I; Neverauskė V; Šepetauskienė E; Serapinas D; Mačinskas Š; Šitkauskienė B; Bajoriūnienė I; Vaičiūnienė R; Valius L
    Medicina (Kaunas); 2022 Mar; 58(3):. PubMed ID: 35334616
    [No Abstract]   [Full Text] [Related]  

  • 36. The Impact of COVID-19 Confinement on Cognition and Mental Health and Technology Use Among Socially Vulnerable Older People: Retrospective Cohort Study.
    Dura-Perez E; Goodman-Casanova JM; Vega-Nuñez A; Guerrero-Pertiñez G; Varela-Moreno E; Garolera M; Quintana M; Cuesta-Vargas AI; Barnestein-Fonseca P; Gómez Sánchez-Lafuente C; Mayoral-Cleries F; Guzman-Parra J
    J Med Internet Res; 2022 Feb; 24(2):e30598. PubMed ID: 35049505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.
    Leaviss J; Davis S; Ren S; Hamilton J; Scope A; Booth A; Sutton A; Parry G; Buszewicz M; Moss-Morris R; White P
    Health Technol Assess; 2020 Sep; 24(46):1-490. PubMed ID: 32975190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
    Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
    Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials.
    Mannick JB; Teo G; Bernardo P; Quinn D; Russell K; Klickstein L; Marshall W; Shergill S
    Lancet Healthy Longev; 2021 May; 2(5):e250-e262. PubMed ID: 33977284
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.